Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in severe hypertension
Renal sympathetic denervation (RDN) has been and is still proposed as a new treatment modality in patients with apparently treatment resistant hypertension (TRH), a condition defined as persistent blood pressure elevation despite prescription of at least 3 antihypertensive drugs including a diuretic...
Main Authors: | Fadl Elmula, Fadl Elmula M., Larstorp, Anne C., Kjeldsen, Sverre E., Persu, Alexandre, Jin, Yu, Staessen, Jan A. |
---|---|
Format: | Online |
Language: | English |
Published: |
Frontiers Media S.A.
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321349/ |
Similar Items
-
Renal Denervation after Symplicity HTN-3: An Update
by: Persu, Alexandre, et al.
Published: (2014) -
Renal denervation after the symplicity HTN-3 trial
by: Warchoł-Celińska, Ewa, et al.
Published: (2014) -
SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
by: Patel, Hitesh C, et al.
Published: (2014) -
SYMPLICITY HTN-3 results to be announced: a mystery or a story foretold?
by: Staessen, Jan A, et al.
Published: (2014) -
Retrospective morphometric study of the suitability of renal arteries for renal denervation according to the Symplicity HTN2 trial criteria
by: Schönherr, Elisabeth, et al.
Published: (2016)